מדינה: קנדה
שפה: אנגלית
מקור: Health Canada
SILDENAFIL (SILDENAFIL CITRATE)
GENMED A DIVISION OF PFIZER CANADA ULC
G04BE03
SILDENAFIL
50MG
TABLET
SILDENAFIL (SILDENAFIL CITRATE) 50MG
ORAL
4/8
Prescription
PHOSPHODIESTERASE TYPE 5 INHIBITORS
Active ingredient group (AIG) number: 0136261002; AHFS:
CANCELLED POST MARKET
2015-08-03
_ _ _GD-SILDENAFIL* (sildenafil citrate) Product Monograph _ _Page 1 of 49 _ PRODUCT MONOGRAPH GD-SILDENAFIL * sildenafil as sildenafil citrate Tablets 25 mg, 50 mg and 100 mg cGMP-Specific Phosphodiesterase Type 5 Inhibitor Treatment of Erectile Dysfunction Submission Control No: 193905 GenMed, a division of Pfizer Canada Inc. 17,300 TranCanada Highway Kirkland, Quebec H9J 2M5 *TM Pfizer Canada Inc. GenMed, a division of Pfizer Canada Inc., Licensee Date of Preparation: 6 May 2016 _ _ _GD-SILDENAFIL* (sildenafil citrate) Product Monograph _ _Page 2 of 49 _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS ....................................................................................................7 DRUG INTERACTIONS ..................................................................................................12 DOSAGE AND ADMINISTRATION ..............................................................................16 OVERDOSAGE ................................................................................................................17 ACTION AND CLINICAL PHARMACOLOGY ............................................................18 STORAGE AND STABILITY ..........................................................................................21 SPECIAL HANDLING INSTRUCTIONS .......................................................................21 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................21 PART II: SCIENTIFIC INFORMATION ...............................................................................22 PHARMACEUTICAL INFORMATION ............................... קרא את המסמך השלם